PT  - JOURNAL ARTICLE
AU  - Ye, Zezhong
AU  - George, Ajit
AU  - Wu, Anthony T.
AU  - Niu, Xuan
AU  - Lin, Joshua
AU  - Adusumilli, Gautam
AU  - Cross, Anne H.
AU  - Sun, Peng
AU  - Song, Sheng-Kwei
TI  - Diffusion Histology Imaging to Improve Lesion Detection and Classification in Multiple Sclerosis
AID  - 10.1101/19009126
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19009126
4099  - http://medrxiv.org/content/early/2019/10/22/19009126.short
4100  - http://medrxiv.org/content/early/2019/10/22/19009126.full
AB  - Background Diagnosing MS through magnetic resonance imaging (MRI) requires extensive clinical experience and tedious work. Furthermore, MRI-indicated MS lesion locations rarely align with the patients’ symptoms and often contradict with pathology studies. Our lab has developed and modified a novel diffusion basis spectrum imaging (DBSI) technique to address the shortcomings of MRI-based MS diagnoses. Although primary DBSI metrics have been demonstrated to be associated with axonal injury/loss, demyelination and inflammation, a more detailed analysis using multiple DBSI-structural metrics to improve the accuracy of MS lesion detection and differentiation is still needed. Here we report that Diffusion Histology Imaging (DHI), an improved approach that combines a deep neural network (DNN) algorithm with improved DBSI analyses, accurately detected and classified various MS lesion types.Methods Thirty-eight multiple sclerosis patients were scanned with T2-weighted imaging (T2WI) using fluid attenuated inversion recovery (FLAIR), T1-weighted imaging (T1WI) using magnetization-prepared rapid acquisition with gradient echo (MPRAGE), magnetization transfer contrast (MTR) imaging and diffusion-weighted imaging. The imaging results identified 43,261 voxels from 91 persistent black hole (PBH) lesions, 89 persistent gray hole (PGH) lesions, 16 acute gray hole (AGH) lesions, 189 non-black hole (NBH) lesions and 113 normal-appearing white matter (NAWM) areas. Data extracted from these lesions were randomly split into training, validation, and testing groups with an 8:1:1 ratio. The DNN was constructed with 10 fully-connected hidden layers using TensorFlow 2.0 in Python. Batch normalization and dropout regularization were used for model optimization.Results Each MS lesion type had unique DBSI derived diffusion metric profiles. Based on these DBSI diffusion metric profiles, DHI achieved a 93.6% overall concordance with neurologist determinations of all five MS lesions, compared with 74.3% from conventional MRI (cMRI)-DNN model, 78.2% from MTR-DNN model, and 80% from DTI-DNN model. DHI also achieved greater performances on detecting individual MS lesion types compared to other models. Specifically, DHI showed great performances on prediction of PBH (AUC: 0.991; F1-score: 0.923), PGH (AUC: 0.977; F1-score: 0.823) and AGH (AUC: 0.987; F1-score: 0.887), which significantly outperformed other models.Conclusions DHI significantly improves the detection and classification accuracy for various MS lesion types, which could greatly aid the clinical decisions of neurologists and neuroradiologists. The efficacy and efficiency of this DNN model shows great promise for clinical application.Competing Interest StatementDr. Anne H. Cross has performed consulting for: Biogen, Celgene, EMD Serono, Genentech/Roche, and Novartis, all of which have no direct relation to the current study. Other authors declare no competing interests, financial or otherwise.Clinical TrialThis study is not a randomized controlled trial and the experimental protocol has been published before. Thus, the study was not registered as a clinical trial.Funding StatementThis study was supported by the National Institutes of Health (NIH) P01 NS059560.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesThe datasets and codes from this study are available from the corresponding author on reasonable request.